The effect of SARS-CoV-2 mRNA vaccination on AMH concentrations in infertile women

Research question: Does SARS-CoV-2 mRNA vaccination affect the ovarian reserve of infertile women undergoing IVF? Design: This was a prospective observational study at a single university-affiliated IVF unit that included infertile women aged 18-44 years who were undergoing IVF/intracytoplasmic sperm injection between November 2020 and September 2021, had received two doses of SARS-CoV-2 mRNA vaccination and had undergone measurement of baseline anti-Mullerian hormone (AMH) concentration within the 12 months preceding their recruitment. AMH concentrations before and after vaccination were evaluated and compared. Results: Overall, 31 women were included in the study. The median AMH concentrations before and after COVID-19 vaccine were comparable (1.7 versus 1.6 g/ml, respectively, P = 0.96). No correlation was found between the participant's anti-COVID-19 antibody titre and the change in AMH concentration. Conclusions: SARS-CoV-2 mRNA vaccination does not adversely affect ovarian reserve, as shown by comparing serum AMH concentrations before and after vaccination. These findings may serve as a counselling tool for clinicians to reassure women undergoing fertility treatment that SARS-CoV-2 mRNA vaccination is safe.

Automated summary

The study found that SARS-CoV-2 mRNA vaccination did not negatively affect ovarian reserve, as demonstrated by comparable serum AMH concentrations before and after vaccination. This suggests that mRNA vaccination is safe for women undergoing fertility treatment.